Tacrolimus Monotherapy is Safe in Immunologically Low-Risk Kidney Transplant Recipients: A Randomized-Controlled Pilot Study

In this randomized-controlled pilot study, the feasibility and safety of tacrolimus monotherapy in immunologically low-risk kidney transplant recipients was evaluated [NTR4824, www.trialregister.nl]. Low immunological risk was defined as maximal 3 HLA mismatches and the absence of panel reactive ant...

Descripción completa

Detalles Bibliográficos
Autores principales: de Weerd, Annelies E., Fatly, Zainab Al, Boer-Verschragen, Marieken, Kal-van Gestel, Judith A., Roelen, Dave L., Dieterich, Marjolein, Betjes, Michiel G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Health Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637544/
https://www.ncbi.nlm.nih.gov/pubmed/36353052
http://dx.doi.org/10.3389/ti.2022.10839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637544/
https://www.ncbi.nlm.nih.gov/pubmed/36353052
http://dx.doi.org/10.3389/ti.2022.10839

Ejemplares similares